SERPLULIMAB for Non-small cell lung cancer: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 32 adverse event reports in the FDA FAERS database where SERPLULIMAB was used for Non-small cell lung cancer.
Most Reported Side Effects for SERPLULIMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Neutrophil count decreased | 19 | 13.9% | 2 | 13 |
| Platelet count decreased | 18 | 13.1% | 2 | 11 |
| Pneumonia | 17 | 12.4% | 7 | 10 |
| White blood cell count decreased | 17 | 12.4% | 1 | 13 |
| Anaemia | 15 | 11.0% | 0 | 6 |
| Myelosuppression | 13 | 9.5% | 5 | 3 |
| Neutropenia | 11 | 8.0% | 0 | 2 |
| Nausea | 10 | 7.3% | 0 | 1 |
| Thrombocytopenia | 10 | 7.3% | 2 | 2 |
| Off label use | 8 | 5.8% | 6 | 0 |
| Pneumonitis | 8 | 5.8% | 0 | 2 |
| Pyrexia | 8 | 5.8% | 3 | 2 |
| Rash | 8 | 5.8% | 0 | 0 |
| Alanine aminotransferase increased | 7 | 5.1% | 0 | 3 |
| Aspartate aminotransferase increased | 7 | 5.1% | 0 | 3 |
Other Indications for SERPLULIMAB
Small cell lung cancer extensive stage (16)
Squamous cell carcinoma of lung (16)
Lung neoplasm malignant (13)
Small cell lung cancer (6)
Other Drugs Used for Non-small cell lung cancer
NIVOLUMAB (9,987)
CARBOPLATIN (7,939)
PEMBROLIZUMAB (6,893)
OSIMERTINIB (6,358)
PEMETREXED (5,179)
PACLITAXEL (4,609)
ATEZOLIZUMAB (4,459)
BEVACIZUMAB (4,136)
DURVALUMAB (3,396)
ERLOTINIB (3,359)